• Helen W Sullivan, Kathryn J Aikin, Jennifer Berktold, Karen L Stein, and Victoria J Hoverman.
• From the US Food and Drug Administration, Silver Spring, MD (HWS, KJA); Westat, Rockville, MD (JB, KLS, VJH). Helen.sullivan@fda.hhs.gov.
• J Am Board Fam Med. 2020 Mar 1; 33 (2): 279-283.

BackgroundDirect-to-consumer prescription drug advertising is prevalent and affects patient care. Previous research that examined its effect on the patient-provider relationship predates many changes in the advertising and medical landscape that have occurred in the last decade, such as the rise in online promotion and the push for value-based medicine.MethodsWe conducted a nationally representative mail-push-to-web survey of 1744 US adults in 2017 to explore how patients view the effects of direct-to-consumer prescription drug advertising on patient-provider interactions.ResultsMost respondents (76%) said they were likely to ask a health care provider about advertised drugs; 26% said they had already done so. Among the 26% of respondents who talked to a health care provider about a specific prescription drug they saw advertised, 16% said they received a prescription for the advertised drug. Few respondents (5%) reported that advertising had caused conflict with a health care provider, 16% said it had caused them to question their provider's advice, and 23% said they were likely to look for a different provider if their provider refused to prescribe a requested brand name drug.DiscussionThese results suggest that direct-to-consumer advertising is driving some patients to discuss specific products with their health care providers but that most patients do not believe advertising has a negative influence on the patient-provider interaction itself.© Copyright 2020 by the American Board of Family Medicine.

11 keywords...

hide…